65,437 trials
COVID-19
Primary: Number of Participants With Clinical Response in Maximum Temperature (Tmax) — 8; 16 Participants
Atopic Dermatitis
Primary: Percent Change From Baseline to Week 16 in Eczema Area and Severity Index (EASI) Score — -48.33; -49.72; -61.07; -57.35 percentage of score change — p=< 0.001
Central Nervous System Lymphoma · Malignant Glioma · Metastatic Malignant Neoplasm in the Brain
Primary: Utility of Femumoxytol and Gadolinium Based Contrast Agents for Improved Imaging Biomarkers of Malignant Brain Tumors in a Single Session by Comparing Dynamic Contrast…
Newborn Jaundice
Primary: BCB - TSB Correlation — 0.82 correlation coefficient — p=<.001
Renal Cancer · Renal Ischemia
Primary: Percent Change From Baseline in eGFR — -10.7; -9.4 percent change in eGFR
Small Cell Lung Cancer
Primary: Duration of Severe (Grade 4) Neutropenia in Cycle 1 — 8; 1; 2; 14 days — p=<0.0001
Severe Hemophilia A
Primary: Number of Participants With Factor VIII (FVIII) Inhibitor Development — 0 Participants
Post-Traumatic Stress Disorder
Primary: Treatment Efficacy as Measured by Change in Clinician-Administered Post Traumatic Stress Disorder Score for Diagnostic and Statistical Manual of Mental Disorders, 5th…
Contraception
Primary: Changes From Baseline in the Post Coital Test Results (PCT) Due to Device Use. — 0; 26 Participants
Myeloid Hematological Malignancies
Primary: Overall Survival at 100 Days, 1 Year, and 3 Years After Umbilical Cord Blood Transplant in Pediatric Patients. — 0.923; 0.923; 0.923 probability of overall survival
Respiratory Syncytial Viruses
Primary: Respiratory Syncytial Virus (RSV) Viral Load-time Curve From Immediately Prior to First Dose of JNJ-53718678 Through Day 5 (AUC [Day 1-5]) — 26.13; 25.10 log10…
End Stage Renal Disease · Vascular Access Patency
Primary: Feasibility and Safety of Ticagrelor in Hemodialysis Patients — 1; 3 Participants — p=0.32
Neuroblastoma
Primary: Objective Tumor Response After One Course of Therapy — 5; 5; 11 Participants
Metastatic Castration Resistant Prostate Cancer
Primary: Confirmed Objective Response Rate (ORR) by Gene in Patients With Measurable Disease at Baseline Per Central Independent Radiology Review (IRR) — 45.7; 0.0; 0.0; 0.0…
Polycystic Ovary Syndrome
Primary: Percentage of Menstrual Cycle Responders — 7.7; 0; 0; 0 percentage of participants — p=0.300